MetaADEDB 2.0 @ LMMD
lanreotide
(PUDHBTGHUJUUFI-SCTWWAJVSA-N)
Structure
SMILES
NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N[C@H](C(=O)N)[C@H](O)C)NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)N)Cc1c[nH]c2c1cccc2
Molecular Formula:
C54H69N11O10S2
Molecular Weight:
1096.320
Log P:
5.3483
Hydrogen Bond Acceptor:
22
Hydrogen Bond Donor:
13
TPSA:
405.68
CAS Number(s):
108736-35-2
Synonym(s)
1.
lanreotide
2.
188Re-lanreotide
3.
2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
4.
BIM 23014
5.
BIM 23014C
6.
BIM-23014
7.
DC 13-116
8.
DC-13-116
9.
DC13-116
10.
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
11.
Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)-Thr-NH2
12.
Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2
13.
Somatulin
14.
Somatulina
15.
Somatuline
16.
lanreotide acetate
17.
lanreotide-SR
18.
naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
19.
naphthyl-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2
External Link(s)
MeSHC060347
PubChem Compound6918011
BindingDB82470
CHEMBLCHEMBL1201185
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1FatigueFAERS: 6US FAERS
2Disease ProgressionFAERS: 5US FAERS
3Abdominal PainFAERS: 2US FAERS
4AnxietyFAERS: 2US FAERS
5ConstipationFAERS: 2US FAERS
6FlatulenceFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
7Gastrointestinal obstructionFAERS: 2US FAERS
8HeadacheFAERS: 2US FAERS
9Intestinal ObstructionFAERS: 2US FAERS
10NauseaFAERS: 2US FAERS
11Pancreatic Enzymes DecreasedFAERS: 2US FAERS
12Abdominal InfectionFAERS: 1US FAERS
13AlopeciaFAERS: 1US FAERS
14ArthralgiaFAERS: 1US FAERS
15Back PainFAERS: 1US FAERS
16Bile acid malabsorptionFAERS: 1US FAERS
17Carcinoid Heart DiseaseFAERS: 1US FAERS
18CholangitisFAERS: 1US FAERS
19CholelithiasisFAERS: 1US FAERS
20ColectomyFAERS: 1US FAERS
21Congenital cystic kidney diseaseFAERS: 1US FAERS
22CystitisFAERS: 1US FAERS
23DehydrationFAERS: 1US FAERS
24FibrosisFAERS: 1US FAERS
25FlushingFAERS: 1US FAERS
26Gastrointestinal bacterial overgrowthFAERS: 1US FAERS
27Gastrointestinal stoma complicationFAERS: 1US FAERS
28HepatotoxicityFAERS: 1US FAERS
29HerniaFAERS: 1US FAERS
30HypersensitivityFAERS: 1US FAERS
31Impaired quality of lifeFAERS: 1US FAERS
32Inappropriate schedule of product administrationFAERS: 1US FAERS
33Incorrect dose administeredFAERS: 1US FAERS
34Injection site massFAERS: 1US FAERS
35Injection site painFAERS: 1US FAERS
36MeningiomaFAERS: 1US FAERS
37Mood swingsFAERS: 1US FAERS
38NephrectomyFAERS: 1US FAERS
39PneumoniaFAERS: 1US FAERS
40PruritusFAERS: 1US FAERS
41Respiratory FailureFAERS: 1US FAERS
42SepsisFAERS: 1US FAERS
43StressFAERS: 1US FAERS
44SwellingFAERS: 1US FAERS
45TremorFAERS: 1US FAERS
46UrticariaFAERS: 1US FAERS
47VomitingFAERS: 1US FAERS
48Weight decreasedFAERS: 1US FAERS
49DizzinessCanada Vigilance: 1Canada Vigilance
50General physical health deteriorationCanada Vigilance: 1Canada Vigilance
51Peripheral swellingCanada Vigilance: 1Canada Vigilance
52Subcutaneous AbscessCanada Vigilance: 1Canada Vigilance
53skin abrasionCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.